BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the Company’s Covid-T™ program. Read full article here: https://equity.guru/2021/06/14/biovaxys-technology-biov-c-receives-positive-fda-response/
![BioVaxys - 14-06- Press Release Thumbnails](https://e4njohordzs.exactdn.com/wp-content/uploads/2021/06/BioVaxys-14-06-Press-Release-Thumbnails-1024x576.jpg?strip=all&lossy=1&ssl=1)